🔗 Share this article

While the US proceeds with historic adjustments to its immunization schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning COVID-19 vaccinations during the pandemic and has zeroed in on alleged deaths after COVID-19 vaccination in her recent tenure at the FDA.

Proposed Changes to Childhood Immunization Program

Health officials planned to announce radical changes to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US at odds with many the world with no evidence for improved outcomes. This reveal has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to run the office this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the drug and biologics divisions as Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some childhood immunization guidelines in the US so as to align more like the Danish model, a nation with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – typically the purview of Prasad, director of the FDA’s CBER – instead of drug regulation.

Concerns Over Qualifications

Høeg has no obvious track record in drug development, oversight or administrative roles, which has been typical for former directors of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in leading a major agency. She is not an expert in industry regulation.”

Former heads of the center would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who ran CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock pointed out.

“Many people just zeroes in on the innovative therapies, but the generic drug division approves thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those need to be looked after,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major management component to the position, which supervises in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment represents greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions rely on inaccurate presumptions”.

“Her experience aligns with the functions of her position,” the official stated, noting the months Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed expedited drug-approval program that reportedly worried her predecessors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent regulations of most medications, aside from shots.”

Established Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if concerning, past, Howard observe. She authored a research paper using unconfirmed crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the current administration featured revising rules for new vaccines and discontinuing “optional” vaccines, she said post-election on a audio program. At the agency, Dr. Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccinations.

“She is an complete true believer who starts off with her preconceived notions and works backwards to fit the science in a very disingenuous, untruthful way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|